Inclusion Criteria:  The patient was at least 18 years old and had reported grade 1 or higher neuropathic symptoms for more than 2 weeks; Patients were screened for eligibility by the investigator prior to enrollment, including verification of baseline neuropathic symptoms. Patients had a diagnosis of stage I, II, or IIIA breast cancer; Have completed at least 2 weeks of chemotherapy; Higher scores indicate more severe symptoms; Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent); Eastern Cooperative Oncology Group (ECOG ) score of physical condition (0-1); Patients with previous local recurrence were eligible; The basic indexes were consistent, and the blood routine and ECG were normal.  Exclusion Criteria:  patients with needle phobia; Low platelet count (<50 000); co-morbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels <10 g/dl and haematocrit <30; anaemia on active pharmacological treatment or receiving blood transfusion or steroids; having metastatic or recurrent disease, history of preexisting peripheral neuropa- thy prior to chemotherapy, uncontrolled seizure disorder, unstable cardiac disease or myocardial infarction within 6 months prior to study entry; Being pregnant or nursing, or having used acupuncture for peripheral neuropathy within 6 months prior to study entry; Life expectancy <6 months; Lymphedema of limbs;